AIKIDO PHARMA INC (AIKI) Stock Price, Quote, News and Overview
NASDAQ:AIKI - Nasdaq - US0088753043 - Common Stock - Currency: USD
AIKI Quote, Performance and Key Statistics
NASDAQ:AIKI (12/21/2022, 8:17:10 PM)
3.56
+0.01 (+0.28%)
The current stock price of AIKI is 3.56 USD. In the past month the price decreased by -10.1%. In the past year, price decreased by -67.28%.
AIKI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AIKI
Company Profile
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
Company Info
AIKIDO PHARMA INC
One Rockefeller Plaza, 11Th Floor
New York City NEW YORK 10020 US
CEO: Anthony Hayes
Employees: 4
Company Website: https://aikidopharma.com/
Phone: 13473217646.0
AIKIDO PHARMA INC / AIKI FAQ
What is the stock price of AIKIDO PHARMA INC today?
The current stock price of AIKI is 3.56 USD. The price increased by 0.28% in the last trading session.
What is the ticker symbol for AIKIDO PHARMA INC stock?
The exchange symbol of AIKIDO PHARMA INC is AIKI and it is listed on the Nasdaq exchange.
On which exchange is AIKI stock listed?
AIKI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AIKIDO PHARMA INC stock?
7 analysts have analysed AIKI and the average price target is 16.32 USD. This implies a price increase of 358.43% is expected in the next year compared to the current price of 3.56. Check the AIKIDO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AIKIDO PHARMA INC worth?
AIKIDO PHARMA INC (AIKI) has a market capitalization of 19.53M USD. This makes AIKI a Nano Cap stock.
How many employees does AIKIDO PHARMA INC have?
AIKIDO PHARMA INC (AIKI) currently has 4 employees.
What are the support and resistance levels for AIKIDO PHARMA INC (AIKI) stock?
AIKIDO PHARMA INC (AIKI) has a resistance level at 3.57. Check the full technical report for a detailed analysis of AIKI support and resistance levels.
Should I buy AIKIDO PHARMA INC (AIKI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AIKI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AIKI, evaluating the profitability, health, valuation and growth aspects
- AIKIDO PHARMA INC (AIKI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AIKIDO PHARMA INC (AIKI) Sales and EPS estimates to see what analysts future expectations are.
- AIKIDO PHARMA INC (AIKI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AIKIDO PHARMA INC (AIKI) Insider and Institutional Ownership to learn about the owners and their transactions.
- AIKIDO PHARMA INC (AIKI) Stock Chart to make your own analysis
- AIKIDO PHARMA INC (AIKI) Latest news and press-releases to stay up to date.
Does AIKIDO PHARMA INC (AIKI) stock pay dividends?
AIKI does not pay a dividend.
When does AIKIDO PHARMA INC (AIKI) report earnings?
AIKIDO PHARMA INC (AIKI) will report earnings on 2023-03-27.
What is the Price/Earnings (PE) ratio of AIKIDO PHARMA INC (AIKI)?
AIKIDO PHARMA INC (AIKI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.37).
AIKI Technical Analysis
AIKI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AIKI. The financial health of AIKI is average, but there are quite some concerns on its profitability.
AIKI Financial Highlights
Over the last trailing twelve months AIKI reported a non-GAAP Earnings per Share(EPS) of -3.37. The EPS decreased by -879.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AIKI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AIKI. The Buy consensus is the average rating of analysts ratings from 7 analysts.